The isolation and synthesis of desoxycorticosterone by Reichstein1 and its successful application to the therapy of adrenal insufficiency by Thorn and his associates2 have led naturally to the hope that this new synthetic preparation will bear the same relationship to the adrenal cortex and to Addison's disease that insulin has borne to the pancreas and to diabetes mellitus. The clinical studies of Cleghorn,3 of Levy Simpson,4 of Dryerre5 and of Ferrebee, Ragan, Atchley and Loeb6 have corroborated for the most part the therapeutic results of Thorn but have revealed, nevertheless, several complicating dangers in the use of this preparation which must necessarily receive further attention before desoxycorticosterone can safely be given unqualified endorsement for general use. Investigations by McCullagh,7 by Thompson,8 and by Rynearson9 and Wilder10 and their associates have likewise demonstrated serious difficulties arising out of the use of
GORDON ES. THE USE OF DESOXYCORTICOSTERONE AND ITS ESTERS IN THE TREATMENT OF ADDISON'S DISEASE. JAMA. 1940;114(26):2549–2551. doi:10.1001/jama.1940.62810260008009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: